Maynard Um
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Kazia Therapeutics (KZIA)
-
-
-
-
-
-
-
Kazia Therapeutics (KZIA) Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer
-
-
-
-
-
-
-
Kazia Therapeutics (KZIA) Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metasta
-
-
-
-
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

